Agios Heads Toward Pivotal Study As FDA Places Hold On Backup
Executive Summary
Biotech’s decision on which candidate to advance to pivotal studies in pyruvate-kinase R deficiency is clarified as backup candidate AG-519 is placed on clinical hold and shelved. Agios hopes to bring the first disease-modifying PKD drug therapy to market.